Eli Lilly (LLY) Offering Possible 7.76% Return Over the Next 37 Calendar Days

Eli Lilly's most recent trend suggests a bullish bias. One trading opportunity on Eli Lilly is a Bull Put Spread using a strike $105.00 short put and a strike $95.00 long put offers a potential 7.76% return on risk over the next 37 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $105.00 by expiration. The full premium credit of $0.72 would be kept by the premium seller. The risk of $9.28 would be incurred if the stock dropped below the $95.00 long put strike price.

The 5-day moving average is moving up which suggests that the short-term momentum for Eli Lilly is bullish and the probability of a rise in share price is higher if the stock starts trending.

The 20-day moving average is moving up which suggests that the medium-term momentum for Eli Lilly is bullish.

The RSI indicator is at 65.13 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here

LATEST NEWS for Eli Lilly

Pharmaceutical groups should invest in public health systems
Sun, 11 Aug 2019 11:02:05 +0000
David Ricks writes that “governments face a clear choice. Mr Ricks, chief executive of Eli Lilly and president of the International Federation of Pharmaceutical Manufacturers & Associations, suggests that drug development should be incentivised in the private sector by extending data exclusivity to further encourage pharmaceutical companies to invest in Alzheimer’s research. In the first instance, it is difficult to see how a public health problem is best tackled by keeping intellectual property in the private sector for even longer than is currently the case.

US patients struggle to obtain Eli Lilly’s half-price insulin
Sun, 11 Aug 2019 04:16:21 +0000
US diabetes patients are struggling to obtain Eli Lilly’s half-price insulin, which it unveiled shortly before being grilled by Congress about the soaring price of the essential medicine. Only about 3 per cent of insurance claims for Eli Lilly’s insulin were for the cheaper, generic version Insulin Lispro, compared with 97 per cent for its brand name Humalog, according to recent data from GoodRx, an app that tracks drug prices. Many pharmacists do not know that the cheaper version is available — and other patients cannot access it because their insurance or pharmacy benefit manager has not put it on formulary, the list of drugs that are covered.

Dividend Investors: Don't Be Too Quick To Buy Eli Lilly and Company (NYSE:LLY) For Its Upcoming Dividend
Sat, 10 Aug 2019 12:53:06 +0000
Eli Lilly and Company (NYSE:LLY) is about to trade ex-dividend in the next 3 days. You can purchase shares before the…

Dicerna Pharmaceuticals Inc (DRNA) Q2 2019 Earnings Call Transcript
Sat, 10 Aug 2019 00:05:28 +0000
DRNA earnings call for the period ending June 30, 2019.

U.S. Court of Appeals Rules in Favor of Lilly in Alimta Alternate Salt Form Patent Lawsuit
Fri, 09 Aug 2019 16:17:00 +0000
INDIANAPOLIS, Aug. 9, 2019 /PRNewswire/ — Eli Lilly and Company (LLY) today announced that the U.S. Court of Appeals for the Federal Circuit ruled in favor of Lilly, confirming that the Alimta® (pemetrexed for injection) vitamin regimen patent would be infringed by competitors that had stated their intent to market alternative salt forms of pemetrexed prior to the patent's expiration in May 2022. The ruling came in the appeals of U.S. District Court decisions in the cases of Eli Lilly and Company v. Dr. Reddy's Laboratories and Eli Lilly and Company v. Hospira, Inc. Previous rulings in Lilly's favor had precluded the generic companies from launching the alternative salt forms until the patent expires.

Related Posts

 

MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.


This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.


The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The www.MarketTamer.com educational training program and software services are provided to improve financial understanding.


The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.